Not yet recruiting NCT07011212
In Search of the Correct Diagnosis of Beta-lactam Allergy: From the Validation of a Risk Stratification Tool to Accurate Endotyping
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: BL-Predicter.
- Who it may be relevant to
- Registry conditions: Drug Allergy. Basic parameters: from 14 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Testing a clinical decision tool (BL-Predictor)
Interventions
- Diagnostic test BL-Predicter
To Clinically validate the BL-Predictor toll by a randomised conytrolled ttrial
Primary outcome measures
- The main goal of this project is to test a cliniacl decision toll to stratify BL allergic pataients in low and mediaum- anf high-risk [Time frame: April 2029- june 2027]
Eligibility criteria
Inclusion criteria
- signed informed consnet
Exclusion criteria
- Use of immunomodulators, antihistamines and corticosteroids
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07011212 · PI24/01913 · PI24/01913